Alkermes has started the Phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation (OIC).

The multicentre randomised double-blind placebo-controlled fixed-dose study will evaluate the safety and efficacy of daily administration of a 100mg dose of ALKS 37 versus placebo for 12 weeks in approximately 80 patients with OIC.

In the study, the primary efficacy endpoint is the change from baseline in the frequency of weekly complete spontaneous bowel movements (CSBMs) during the initial four weeks of the treatment period.

Additional endpoints of the study include the change from baseline in the frequency of weekly spontaneous bowel movements (SBMs), a responder analysis and the median time to first SBM and CSBM following the first dose of ALKS 37.

An earlier Phase 2 study showed ALKS 37 improved gastrointestinal motility and the frequency of bowel movements in patients with OIC, while simultaneously preserving the analgesic effects of opioid treatment.

Alkermes chief medical officer Elliot Ehrich said ALKS 37 has the potential to normalise bowel function in patients being treated with opioids for chronic pain, without affecting their analgesic effects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

”We look forward to seeing the results of both phase 2b studies of ALKS 37 in mid-2012," Ehrich added.